12.04.2016 Views

Nestlé in society Creating Shared Value and meeting our commitments 2015

nestle-csv-full-report-2015-en

nestle-csv-full-report-2015-en

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Nestlé</strong> <strong>in</strong> <strong>society</strong>:<br />

Creat<strong>in</strong>g <strong>Shared</strong> <strong>Value</strong><br />

Nutrition, health<br />

<strong>and</strong> wellness<br />

Rural development<br />

Water<br />

Environmental<br />

susta<strong>in</strong>ability<br />

Human rights<br />

<strong>and</strong> compliance<br />

Our<br />

people<br />

Customer health <strong>and</strong> safety G4-DMA<br />

Our R&D units Role (<strong>and</strong> research themes) <strong>2015</strong> collaborations<br />

(<strong>in</strong>ternal <strong>and</strong> external)<br />

Consumer benefits<br />

<strong>Nestlé</strong> Institute<br />

of Health<br />

Sciences (NIHS)<br />

Biomedical research <strong>in</strong>stitute<br />

specialis<strong>in</strong>g <strong>in</strong> metabolic health,<br />

gastro<strong>in</strong>test<strong>in</strong>al health, bra<strong>in</strong> health<br />

<strong>and</strong> age<strong>in</strong>g.<br />

• Signed research collaboration<br />

agreement with lead<strong>in</strong>g Swiss<br />

biopharmaceutical company AC<br />

Immune <strong>in</strong> September <strong>2015</strong>.<br />

• Began collaborative project with<br />

EpiGen to study sarcopenia at a<br />

molecular level.<br />

• The collaboration aims to<br />

develop a sensitive, m<strong>in</strong>imally<br />

<strong>in</strong>vasive procedure to map the<br />

early stages of Alzheimer’s<br />

disease by apply<strong>in</strong>g antibody<br />

technology provided by the<br />

NIHS.<br />

• Research will <strong>in</strong>dicate how<br />

<strong>in</strong>novative nutritional therapies<br />

can be applied to sarcopenia<br />

sufferers.<br />

Key bus<strong>in</strong>esses Role (<strong>and</strong> research themes) <strong>2015</strong> collaborations<br />

(<strong>in</strong>ternal <strong>and</strong> external)<br />

Consumer/patient benefits<br />

<strong>Nestlé</strong> Health<br />

Science (NHSc)<br />

A wholly owned <strong>Nestlé</strong> subsidiary<br />

engaged <strong>in</strong> advanc<strong>in</strong>g the role of<br />

nutritional therapy to change the<br />

c<strong>our</strong>se of health for consumers,<br />

patients <strong>and</strong> <strong>our</strong> partners <strong>in</strong><br />

healthcare.<br />

• Agreement signed with Lipid<br />

Therapeutics to deliver novel<br />

ulcerative colitis therapy.<br />

• Invested <strong>in</strong> Seres Therapeutics,<br />

to support phase III trials of<br />

SER-109 for the prevention of<br />

recurrent Clostridium difficile<br />

<strong>in</strong>fection (CDI). The US Food <strong>and</strong><br />

Drug Adm<strong>in</strong>istration (FDA)<br />

granted SER-109 orphan drug,<br />

as well as a breakthrough<br />

therapy designation <strong>in</strong> <strong>2015</strong>.<br />

<br />

www.serestheraputics.com<br />

In January 2016: NHSc <strong>and</strong><br />

Seres signed licens<strong>in</strong>g<br />

agreement (see Seres <strong>and</strong>/or<br />

NHSc website, newsroom).<br />

• Launched nutritional solutions<br />

such as Meritene® Mobilis (<strong>in</strong><br />

Europe) <strong>and</strong> Boost® nutritional<br />

dr<strong>in</strong>ks <strong>in</strong> compact sizes (<strong>in</strong> the<br />

United States) to meet the<br />

special needs of the age<strong>in</strong>g body.<br />

• Launched the Compat Ella®<br />

feed<strong>in</strong>g pump, which connects to<br />

patient data systems to ensure<br />

that feed<strong>in</strong>g rates are easily<br />

adjusted to patient needs, thereby<br />

improv<strong>in</strong>g cl<strong>in</strong>ical outcomes <strong>and</strong><br />

reduc<strong>in</strong>g care costs.<br />

• Launched CoMiSS®, an<br />

awareness tool to help primary<br />

healthcare professionals assess<br />

the likelihood of cow’s milk<br />

prote<strong>in</strong> allergy with 80%<br />

effectiveness.<br />

<strong>Nestlé</strong> Sk<strong>in</strong><br />

Health<br />

A wholly owned <strong>Nestlé</strong> subsidiary<br />

focus<strong>in</strong>g on meet<strong>in</strong>g the world’s<br />

<strong>in</strong>creas<strong>in</strong>g sk<strong>in</strong> health needs with a<br />

broad range of <strong>in</strong>novative <strong>and</strong><br />

scientifically proven products.<br />

• Announced plans to build new<br />

SHIELD centres <strong>in</strong> Shanghai,<br />

Ch<strong>in</strong>a, <strong>and</strong> São Paulo, Brazil.<br />

• This global <strong>in</strong>novation network<br />

aims to foster breakthroughs <strong>and</strong><br />

collaboration <strong>in</strong> sk<strong>in</strong> health<br />

through medical <strong>in</strong>vestigation,<br />

education <strong>and</strong> applications.<br />

<strong>Nestlé</strong> Nutrition<br />

Institute (NNI)<br />

Shares lead<strong>in</strong>g science-based<br />

nutrition <strong>in</strong>formation <strong>and</strong> education<br />

with healthcare professionals,<br />

scientists, <strong>and</strong> public health<br />

communities <strong>and</strong> stakeholders.<br />

• In <strong>2015</strong>, NNI supported<br />

13 <strong>in</strong>ternational congresses,<br />

hold<strong>in</strong>g satellite symposia at<br />

9 of them.<br />

• Works with healthcare<br />

professionals.<br />

<strong>Nestlé</strong> <strong>in</strong> <strong>society</strong> – Creat<strong>in</strong>g <strong>Shared</strong> <strong>Value</strong> <strong>and</strong> meet<strong>in</strong>g <strong>our</strong> <strong>commitments</strong> <strong>2015</strong> 51

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!